Cantor Fitzgerald Has Positive View of MIRM FY2025 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for Mirum Pharmaceuticals in a report released on Thursday, February 27th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will earn ($1.40) per share for the year, up from their previous forecast of ($1.55). The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share.

Several other equities research analysts have also recently commented on the company. Citigroup upped their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright upped their price target on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Finally, Robert W. Baird increased their price objective on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a research report on Thursday, February 27th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Mirum Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $58.20.

Mirum Pharmaceuticals Price Performance

Mirum Pharmaceuticals stock opened at $45.22 on Monday. Mirum Pharmaceuticals has a 12 month low of $23.14 and a 12 month high of $54.23. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The business has a 50 day simple moving average of $47.11 and a 200-day simple moving average of $43.46. The stock has a market capitalization of $2.22 billion, a PE ratio of -22.39 and a beta of 0.96.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $99.41 million for the quarter, compared to analysts’ expectations of $96.64 million.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. State Street Corp increased its position in shares of Mirum Pharmaceuticals by 19.9% in the third quarter. State Street Corp now owns 1,793,728 shares of the company’s stock valued at $69,955,000 after buying an additional 297,511 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Mirum Pharmaceuticals by 5.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 328,161 shares of the company’s stock valued at $12,798,000 after buying an additional 17,149 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Mirum Pharmaceuticals by 3.2% in the third quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock valued at $36,519,000 after buying an additional 29,017 shares in the last quarter. GSA Capital Partners LLP increased its position in shares of Mirum Pharmaceuticals by 791.7% in the third quarter. GSA Capital Partners LLP now owns 57,985 shares of the company’s stock valued at $2,261,000 after buying an additional 51,482 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its stake in shares of Mirum Pharmaceuticals by 25.5% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company’s stock valued at $6,021,000 after acquiring an additional 29,545 shares during the last quarter.

Insiders Place Their Bets

In other news, SVP Jolanda Howe sold 750 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $32,115.00. Following the completion of the transaction, the senior vice president now owns 2,926 shares in the company, valued at $125,291.32. This trade represents a 20.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Christopher Peetz sold 7,489 shares of the firm’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total value of $320,678.98. Following the completion of the transaction, the chief executive officer now owns 119,359 shares of the company’s stock, valued at approximately $5,110,952.38. This represents a 5.90 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 40,915 shares of company stock worth $1,897,920. 22.87% of the stock is owned by corporate insiders.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.